Halozyme Therapeutics (HALO) reported Q1 non-GAAP earnings Tuesday of $1.11 per diluted share, up compared with $0.79 a year earlier.
Analysts polled by FactSet expected $0.92.
Revenue for the quarter ended March 31 was $264.9 million, up compared with $195.6 million a year earlier.
Analysts expected $230.1 million.
For 2025, the biopharmaceutical company is now projecting adjusted EPS of $5.30 to $5.70 on revenue of $1.20 billion to $1.28 billion, up from its prior forecast expecting $4.95 to $5.35 per share on revenue of $1.15 billion to $1.23 billion.
Analysts are looking for $5.09 and $1.2 billion, respectively.
Halozyme also said it has authorized a second $250 million stock buyback program as part of its broader $750 million share repurchase plan disclosed in February 2024.
Halozyme shares were more than 6% higher in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.